This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsuruo, T. Articles by Sakurai, Y. Search for Related Content PubMed PubMed Citation Articles by Tsuruo, T. Articles by Sakurai, Y.

Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil¹

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170, Japan

A noncytotoxic dose of verapamil, a coronary vasodilator, enhances the cytotoxicity of vincristine (VCR) and vinblastine in P388 leukemia and its VCR-resistant subline, P388/VCR. When 2.2 to 6.6 µM verapamil was added along with VCR to the P388/VCR culture in vitro, VCR resistance was completely overcome. Verapamil in doses of 50 to 100 mg/kg administered daily for 10 days with VCR also enhances the chemotherapeutic effect of VCR in P388- and, especially, P388/VCR-bearing mice. When approximately 3 times the amount of VCR was given to a P388/VCR bearer as compared to a P388 bearer, VCR resistance was almost completely overcome in vivo with 50 to 100-mg/kg doses of verapamil. The amount of VCR incorporated into P388 cells was larger than that in P388/VCR cells. Verapamil (6.6 µM) enhanced the cellular level of VCR in P388 cells 2-fold and enhanced the level of VCR in P388/VCR cells 10-fold. The amount of VCR in P388/VCR cells reached the same level as that found in P388 cells. The overcoming of VCR resistance in vivo and in vitro could be explained by the effective accumulation of VCR by verapamil in P388/VCR cells mediated by the inhibition of a VCR efflux function of the cells, a mechanism which remains to be solved.

¹ This work was supported by Grant-in-Aid for Cancer Research 401017 from the Ministry of Education, Science, and Culture, Japan.

² To whom requests for reprints should be addressed.

Received 8/ 8/80. Accepted 1/22/81.

This article has been cited by other articles:

				R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, P. V. Baret, M. V. Keniya, K. Tanabe, M. Niimi, A. Goffeau, and B. C. Monk Efflux-Mediated Antifungal Drug Resistance Clin. Microbiol. Rev., April 1, 2009; 22(2): 291 - 321. [Abstract] [Full Text] [PDF]

				S. Ye, D. P. MacEachran, J. W. Hamilton, G. A. O'Toole, and B. A. Stanton Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif Am J Physiol Cell Physiol, September 1, 2008; 295(3): C807 - C818. [Abstract] [Full Text] [PDF]

				H. Devalapally, Z. Duan, M. V. Seiden, and M. M. Amiji Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles Clin. Cancer Res., May 15, 2008; 14(10): 3193 - 3203. [Abstract] [Full Text] [PDF]

				J. Mookerjee Basu, A. Mookerjee, R. Banerjee, M. Saha, S. Singh, K. Naskar, G. Tripathy, P. K. Sinha, K. Pandey, S. Sundar, et al. Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1080 - 1093. [Abstract] [Full Text] [PDF]

				C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol. Cancer Ther., December 1, 2007; 6(12): 3287 - 3296. [Abstract] [Full Text] [PDF]

				S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein) Oncologist, August 1, 2007; 12(8): 927 - 941. [Abstract] [Full Text] [PDF]

				K. Katayama, S. Yoshioka, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein Mol. Cancer Ther., July 1, 2007; 6(7): 2092 - 2102. [Abstract] [Full Text] [PDF]

				T. Saeki, T. Nomizu, M. Toi, Y. Ito, S. Noguchi, T. Kobayashi, T. Asaga, H. Minami, N. Yamamoto, K. Aogi, et al. Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer J. Clin. Oncol., February 1, 2007; 25(4): 411 - 417. [Abstract] [Full Text] [PDF]

				W. Chearwae, S. Shukla, P. Limtrakul, and S. V. Ambudkar Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., August 1, 2006; 5(8): 1995 - 2006. [Abstract] [Full Text] [PDF]

				M. Ballent, A. Lifschitz, G. Virkel, J. Sallovitz, and C. Lanusse MODULATION OF THE P-GLYCOPROTEIN-MEDIATED INTESTINAL SECRETION OF IVERMECTIN: IN VITRO AND IN VIVO ASSESSMENTS Drug Metab. Dispos., March 1, 2006; 34(3): 457 - 463. [Abstract] [Full Text] [PDF]

				S. Yamaguchi, Y. L. Zhao, M. Nadai, H. Yoshizumi, X. Cen, S. Torita, K. Takagi, K. Takagi, and T. Hasegawa Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Telithromycin Transport Antimicrob. Agents Chemother., January 1, 2006; 50(1): 80 - 87. [Abstract] [Full Text] [PDF]

				V. Gouaze, Y.-Y. Liu, C. S. Prickett, J. Y. Yu, A. E. Giuliano, and M. C. Cabot Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs Cancer Res., May 1, 2005; 65(9): 3861 - 3867. [Abstract] [Full Text] [PDF]

				X.-f. Zhou, L. Zhang, E. Tseng, E. Scott-Ramsay, J. J. Schentag, R. A. Coburn, and M. E. Morris NEW 4-ARYL-1,4-DIHYDROPYRIDINES AND 4-ARYLPYRIDINES AS P-GLYCOPROTEIN INHIBITORS Drug Metab. Dispos., March 1, 2005; 33(3): 321 - 328. [Abstract] [Full Text] [PDF]

				M. Benlloch, A. Ortega, P. Ferrer, R. Segarra, E. Obrador, M. Asensi, J. Carretero, and J. M. Estrela Acceleration of Glutathione Efflux and Inhibition of {gamma}-Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity J. Biol. Chem., February 25, 2005; 280(8): 6950 - 6959. [Abstract] [Full Text] [PDF]

				D. Peer, Y. Dekel, D. Melikhov, and R. Margalit Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models Cancer Res., October 15, 2004; 64(20): 7562 - 7569. [Abstract] [Full Text] [PDF]

				D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF]

				D. Trompier, X.-B. Chang, R. Barattin, A. d. M. d'Hardemare, A. Di Pietro, and H. Baubichon-Cortay Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 Cancer Res., July 15, 2004; 64(14): 4950 - 4956. [Abstract] [Full Text] [PDF]

				S. U. C. Sankatsing, J. H. Beijnen, A. H. Schinkel, J. M. A. Lange, and J. M. Prins P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1073 - 1081. [Full Text] [PDF]

				G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]

				Y. Imai, S. Asada, S. Tsukahara, E. Ishikawa, T. Tsuruo, and Y. Sugimoto Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens Mol. Pharmacol., September 1, 2003; 64(3): 610 - 618. [Abstract] [Full Text] [PDF]

				N. Maki, P. Hafkemeyer, and S. Dey Allosteric Modulation of Human P-glycoprotein. INHIBITION OF TRANSPORT BY PREVENTING SUBSTRATE TRANSLOCATION AND DISSOCIATION J. Biol. Chem., May 9, 2003; 278(20): 18132 - 18139. [Abstract] [Full Text] [PDF]

				S. Zhang and M. E. Morris Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1258 - 1267. [Abstract] [Full Text] [PDF]

				Y. Sugimoto, S. Tsukahara, Y. Imai, Y. Sugimoto, K. Ueda, and T. Tsuruo Reversal of Breast Cancer Resistance Protein-mediated Drug Resistance by Estrogen Antagonists and Agonists Mol. Cancer Ther., January 1, 2003; 2(1): 105 - 112. [Abstract] [Full Text] [PDF]

				A. Kanzaki, Y. Takebayashi, X.-Q. Ren, H. Miyashita, S. Mori, S.-i. Akiyama, and Y. Pommier Overcoming Multidrug Drug Resistance in P-Glycoprotein/MDR1-overexpressing Cell Lines by Ecteinascidin 743 Mol. Cancer Ther., December 1, 2002; 1(14): 1327 - 1334. [Abstract] [Full Text] [PDF]

				C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]

				M. Naito, Y. Matsuba, S. Sato, H. Hirata, and T. Tsuruo MS-209, a Quinoline-type Reversal Agent, Potentiates Antitumor Efficacy of Docetaxel in Multidrug-resistant Solid Tumor Xenograft Models Clin. Cancer Res., February 1, 2002; 8(2): 582 - 588. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				R. A. Peck, J. Hewett, M. W. Harding, Y.-M. Wang, P. R. Chaturvedi, A. Bhatnagar, H. Ziessman, F. Atkins, and M. J. Hawkins Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin J. Clin. Oncol., June 15, 2001; 19(12): 3130 - 3141. [Abstract] [Full Text] [PDF]

				E. R. Gaynor, J. M. Unger, T. P. Miller, T. M. Grogan, L. A. White Jr, G. M. Mills, S. P. Balcerzak, M. Varterasian, M. LeBlanc, and R. I. Fisher Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study J. Clin. Oncol., February 1, 2001; 19(3): 750 - 755. [Abstract] [Full Text] [PDF]

				I. Chico, M. H. Kang, R. Bergan, J. Abraham, S. Bakke, B. Meadows, A. Rutt, R. Robey, P. Choyke, M. Merino, et al. Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833 J. Clin. Oncol., February 1, 2001; 19(3): 832 - 842. [Abstract] [Full Text] [PDF]

				D. R. Johnson, R. A. Finch, Z. P. Lin, C. J. Zeiss, and A. C. Sartorelli The Pharmacological Phenotype of Combined Multidrug-Resistance mdr1a/1b- and mrp1-deficient Mice Cancer Res., February 1, 2001; 61(4): 1469 - 1476. [Abstract] [Full Text]

				D. W. Loe, R. G. Deeley, and S. P. C. Cole Verapamil Stimulates Glutathione Transport by the 190-kDa Multidrug Resistance Protein 1 (MRP1) J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 530 - 538. [Abstract] [Full Text]

				C. Wandel, R. B. Kim, S. Kajiji, F. P. Guengerich, G. R. Wilkinson, and A. J. J. Wood P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies Cancer Res., August 1, 1999; 59(16): 3944 - 3948. [Abstract] [Full Text] [PDF]

				J. van Asperen, O. van Tellingen, A. H. Schinkel, and J. H. Beijnen Comparative Pharmacokinetics of Vinblastine after a 96-Hour Continuous Infusion in Wild-Type Mice and Mice Lacking mdr1a P-Glycoprotein J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 329 - 333. [Abstract] [Full Text]

				C. Ziemann, A. Burkle, G. F. Kahl, and K. I. Hirsch-Ernst Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures Carcinogenesis, March 1, 1999; 20(3): 407 - 414. [Abstract] [Full Text] [PDF]

				U. S. H. Svensson, R. Sandström, O. Carlborg, H. Lennernäs, and M. Ashton High In Situ Rat Intestinal Permeability of Artemisinin Unaffected by Multiple Dosing and with No Evidence of P-glycoprotein Involvement Drug Metab. Dispos., February 1, 1999; 27(2): 227 - 232. [Abstract] [Full Text]

				M. C. Cabot, A. E. Giuliano, T.-Y. Han, and Y.-Y. Liu SDZ PSC 833, the Cyclosporine A Analogue and Multidrug Resistance Modulator, Activates Ceramide Synthesis and Increases Vinblastine Sensitivity in Drug-sensitive and Drug-resistant Cancer Cells Cancer Res., February 1, 1999; 59(4): 880 - 885. [Abstract] [Full Text] [PDF]

				M. Egashira, N. Kawamata, K. Sugimoto, T. Kaneko, and K. Oshimi P-Glycoprotein Expression on Normal and Abnormally Expanded Natural Killer Cells and Inhibition of P-Glycoprotein Function by Cyclosporin A and Its Analogue, PSC833 Blood, January 15, 1999; 93(2): 599 - 606. [Abstract] [Full Text] [PDF]

				K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver Pharmacol. Rev., September 1, 1998; 50(3): 387 - 412. [Abstract] [Full Text] [PDF]

				A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. A. M. Mol, L. van Deemter, J. J. M. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins PNAS, April 15, 1997; 94(8): 4028 - 4033. [Abstract] [Full Text] [PDF]

				M. G. Scott, K. G. Hock, D. L. Crimmins, and P. M. Fracasso HPLC method for monitoring SDZ PSC 833 in whole blood Clin. Chem., March 1, 1997; 43(3): 505 - 510. [Abstract] [Full Text] [PDF]

				T. Sumizawa, Z.-S. Chen, Y. Chuman, K. Seto, T. Furukawa, M. Haraguchi, A. Tani, N. Shudo, and S.-I. Akiyama Reversal of Multidrug Resistance-Associated Protein-Mediated Drug Resistance by the Pyridine Analog PAK-104P Mol. Pharmacol., March 1, 1997; 51(3): 399 - 405. [Abstract] [Full Text] [PDF]

				Y. Lavie, H.-t. Cao, A. Volner, A. Lucci, T.-Y. Han, V. Geffen, A. E. Giuliano, and M. C. Cabot Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells J. Biol. Chem., January 17, 1997; 272(3): 1682 - 1687. [Abstract] [Full Text] [PDF]

				A van Helvoort, M. Giudici, M Thielemans, and G van Meer Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity J. Cell Sci., January 1, 1997; 110(1): 75 - 83. [Abstract] [PDF]

				N. Sonveaux, A. B. Shapiro, E. Goormaghtigh, V. Ling, and J.-M. Ruysschaert Secondary and Tertiary Structure Changes of Reconstituted P-glycoprotein. A FOURIER TRANSFORM ATTENUATED TOTAL REFLECTION INFRARED SPECTROSCOPY ANALYSIS J. Biol. Chem., October 4, 1996; 271(40): 24617 - 24624. [Abstract] [Full Text] [PDF]

				C. Duhem, F. Ries, and M. Dicato What does Multidrug Resistance (MDR) Expression Mean in the Clinic? Oncologist, June 1, 1996; 1(3): 151 - 158. [Abstract] [Full Text] [PDF]

				G. D. Eytan, R. Regev, G. Oren, and Y. G. Assaraf The Role of Passive Transbilayer Drug Movement in Multidrug Resistance and Its Modulation J. Biol. Chem., May 31, 1996; 271(22): 12897 - 12902. [Abstract] [Full Text] [PDF]

				M. Tominaga, T. Tominaga, A. Miwa, and Y. Okada Volume-sensitive Chloride Channel Activity Does Not Depend on Endogenous P-glycoprotein J. Biol. Chem., November 17, 1995; 270(46): 27887 - 27893. [Abstract] [Full Text] [PDF]

				C. Cho, A. W. Pruitt, J. J. Corrigan Jr, H. D. Allen, R. Hong, and C. T. Kisker Therapeutic Uses of Calcium Channel-Blocking Drugs in the Young Arch Pediatr Adolesc Med, April 1, 1986; 140(4): 360 - 366. [Abstract] [PDF]